CRISPR Therapeutics AG (MEX:CRSP) Asset Impairment Charge : MXN0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Asset Impairment Charge?

CRISPR Therapeutics AG's Asset Impairment Charge for the three months ended in Mar. 2025 was MXN0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was MXN0.0 Mil.

CRISPR Therapeutics AG Asset Impairment Charge Historical Data

The historical data trend for CRISPR Therapeutics AG's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Asset Impairment Charge Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

CRISPR Therapeutics AG Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

CRISPR Therapeutics AG Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.0 Mil.

CRISPR Therapeutics AG Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

CRSP:USA 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.